Phase 1 N=41 Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.
Chronic Constipation, Methanogenesis
Primary: Change in Methane Production — 10645; 14635 parts per million*minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=25 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Constipation
Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75
Early Phase 1 N=12 Role of Methane in Glycemic Control
Diabetes · Obesity
Primary: Number of Subjects Who Eradicated Methane on Breath Test — 8 participants
N/A N=37 Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
Constipation-predominant Irritable Bowel Syndrome
Primary: Severity of Constipation in Each Arm at Week 1 After Completion of Therapy — 61.2; 28.6 units on a scale
Phase 2 N=79 A Study of the Effect of SYN-010 on Subjects With IBS-C
Irritable Bowel Syndrome With Constipation (IBS-C)
Primary: Change From Baseline in the Area Under the Curve (AUC) of Breath CH4 Production at Day 7 — 99.2; 57.3; 72.7 hours*ppm
Phase 3 N=224 B. Lactis HN019 for Functional Constipation
Constipation
Primary: Whole Gut Transit Time
N/A N=27 Effects of Exercise Training on Pelvic Floor Symptoms and Function in Adults With Constipation
Constipation
Primary: Severity of Constipation Symptoms — 0.96; 0.97; 0.63; 0.67 score on a scale
Phase 3 N=40 Lubiprostone and Mucus Secretion in Patients With Chronic Constipation
Constipation
Primary: Change of Mucus and Mucin Secretion in Patients With Chronic Constipation and in Controls. — 260; 133; 229; 161 mg/hour
Phase 2 N=36 Cheno Effect on Transit in Health and IBS-C
Constipation-predominant Irritable Bowel Syndrome
Primary: Colonic Geometric Center at 24 Hours (GC24) — 3.1; 3.5; 2.2 units on a scale
Phase 4 N=153 The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation
Functional Constipation
Primary: Change of Clostridium Butyricum Miyairi Expression After Probiotics Supplementation in Constipated Children. — 0.00486; 0.0000148; 0.00000189 number of bacteria per mg…
N/A N=225 Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders
Irritable Bowel Syndrome · Colitis, Ulcerative · Crohn Disease
Primary: Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms — 40; 30; 23; 23 microbial species population
N/A N=39 Biomarkers for Intestinal Permeability in Patients With Constipation
Intestinal Diseases · Irritable Bowel Syndrome · Constipation
Primary: Lactulose:C13 Mannitol Excretion Ratio 8-24hrs. — 0.01; 0.02 Ratio — p=0.87
Phase 2 N=12 Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
Neoplasms · Constipation · Opioid-Related Disorders
Primary: Rescue-free Laxation After Administration of Subcutaneous Methylnaltrexone — 33 percentage of participants
Phase 4 N=14 Effects of Gastric Acid on Colonic Microbiome
Clostridium Difficile
Primary: Shannon Diversity Index Measuring Change in Microbiome Diversity — 0.18; 0.14 Shannon index — p=0.71
N/A N=102 Maintenance Treatment for Children With Constipation
Constipation
Primary: Treatment Recovery — 33; 19 participants — p=0.024
Phase 4 N=74 A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
Irritable Bowel Syndrome
Primary: Change in Mean Daily Abdominal Pain — 5.2; 5.3; 3.9; 3.8 score on a scale — p=0.78
Phase 2 N=120 An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation
Functional Gastrointestinal Disorders · Constipation
Primary: Responder of Complete Spontaneous Bowel Movement (CSBM) — 26; 5; 34; 55 participants — p=<0.05
N/A N=40 The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
Constipation · Chronic Idiopathic Constipation · Irritable Bowel Syndrome With Constipation
Primary: Change From Baseline in Colonic Transit Time (CTT) — -727; -15; 366 minutes
Phase 2 N=192 Dose-ranging Efficacy of Polydextrose Supplement on Colonic Transit Time and Symptoms in Adults With Functional Constipation
Functional Constipation
Primary: Change in Colonic Transit Time From Baseline to Day 15 — -1.7; 4.0; 2.5; 2.6 Hours
Phase 4 N=12 Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation
Constipation Drug Induced
Primary: Occurrence of Bowl Movement — 2; 2; 5 Participants
Phase 4 N=230 Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
Opioid-Induced Constipation
Primary: The Proportion of Subjects Who Have a Rescue-free Laxation Response Within 4 Hours After at Least 2 of the First 4 Doses — 62.9; 9.6 percentage of participants — p=<…
N/A N=16 Effect of Kiwifruit on Gastrointestinal Fluid Distribution and Transit in Healthy Volunteers
Constipation · Diet Modification
Primary: Relaxation Time in Ascending Colon — 312; 256 seconds*minutes
Phase 4 N=48 Effect of Methylnaltrexone on GI Transit in Healthy Volunteers
Gastric Motility Disorder
Primary: Colonic Geometric Center at 24 Hours — 2.3; 1.8; 1.9; 2.3 Units on a scale — p=0.902
Phase 2 N=97 A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation
Constipation
Primary: Responder for Complete Spontaneous Bowel Movement (CSBM) — 10; 14; 17; 22 participants — p=<0.05
N/A N=12 Proof of Concept: "Bottom's Up" Seat to Treat Constipation
Constipation Aggravated · Pelvic Floor; Incompetency
Primary: Adverse Events — 0 Participants
Phase 4 N=3 Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
Cystic Fibrosis Gastrointestinal Disease
Primary: Change is Being Assessed: Total Intestinal Transit Time at Baseline and Two Weeks Following Initiation of Therapy — 41; 42 hours
Phase 4 N=13 Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity
Chronic Constipation
Primary: The Number of High-Amplitude Propagating Contractions (HAPC) — 8.7; 2.9 Number of HAPC with amplitude ≥100mmHg — p=0.012
Phase 2 N=6 MTT for Children With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders
Pitt Hopkins Syndrome
Primary: Daily Stool Record (DSR( — -2.3; 0 days
N/A N=250 Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation
Colorectal Cancer
Primary: Comparisons of the Changes of Genera Prevotella by Mg Treatment vs. Placebo in Rectal Mucosa, Swab and Stool Samples — 0.108; 0.245; -0.076; 0.132 percentage of sample…
N/A N=52 Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Irritable Bowel Syndrome · Constipation
Primary: Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline — 5.49; 6.52; -0.16; 0.2 hours